AHNS Consensus Statement on the Use of PD-1 Inhibitors in Treating Advanced Cutaneous Squamous Cell Carcinoma (cSCC)
Cecelia E. Schmalbach, MD, MSc
Karen Choi, MD
Kevin Emerick, MD
Brian Haughley, MD
Scott McLean, MD, PhD
Brian Moore, MD
Miriam O’Leary, MD
T.J. Ow, MD
Primary Survey Goal: The United States Federal Drug Administration (FDA) approved the use of PD-1 inhibitors Cemiplimab and Pembrolizumab to treat advanced cutaneous squamous cell carcinoma (cSCC). A consensus statement put forth by the American Head and Neck Society (AHNS) is required in order to ensure the highest level of evidence based care to our patients.
The statements below were collated following a comprehensive review of the literature to include clinical trials and position statements put forth by our sister societies such as medical and radiation oncology. The draft underwent 4 cycles of review for clarity and consistency with senior leadership in the AHNS Cutaneous Cancer Section. A medical oncologist and radiation oncologist affiliated with the AHNS then reviewed it.
We need your voice in order to publish an impactful AHNS consensus statement. Please click the link below and take 5 minutes to share your level of agreement on the presented statements. A score of 7 and above will be considered as agreement.
Thank you in advance for your time,
Cecelia E. Schmalbach, MD, MSc